Research programme: antibody therapies - Zymeworks/XOMA
Alternative Names: TAE™; ZymeCAD™Latest Information Update: 02 Oct 2021
At a glance
- Originator XOMA; Zymeworks
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 28 Oct 2014 Discontinued for Undefined indication in Canada (Parenteral)
- 28 Oct 2014 Discontinued for Undefined indication in USA (Parenteral)
- 15 May 2009 Early research in Undefined indication in Canada (Parenteral)